Cargando…
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309701/ https://www.ncbi.nlm.nih.gov/pubmed/33196101 http://dx.doi.org/10.2340/00015555-3692 |
_version_ | 1784753225609510912 |
---|---|
author | ATALAY, Selma VAN DEN REEK, Juul M. P. A. OTERO, Marisol E. NJOO, Marcellus D. MOMMERS, Johannes M. OSSENKOPPELE, Paul M. KOETSIER, Marjolein I. BERENDS, Maartje A. VAN DE KERKHOF, Peter C. M. GROENEWOUD, Hans M. M. DEN BROEDER, Alfons A. DE JONG, Elke M. G. J. KIEVIT, Wietske |
author_facet | ATALAY, Selma VAN DEN REEK, Juul M. P. A. OTERO, Marisol E. NJOO, Marcellus D. MOMMERS, Johannes M. OSSENKOPPELE, Paul M. KOETSIER, Marjolein I. BERENDS, Maartje A. VAN DE KERKHOF, Peter C. M. GROENEWOUD, Hans M. M. DEN BROEDER, Alfons A. DE JONG, Elke M. G. J. KIEVIT, Wietske |
author_sort | ATALAY, Selma |
collection | PubMed |
description | A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The aim of the current study was to perform a cost-utility analysis with a 12-month time horizon alongside this trial, using prospectively measured healthcare costs and quality-adjusted life years, based on Short-Form Six-Dimension utilities. Bootstrap analyses were used to calculate the decremental cost-utility ratio and the incremental net monetary benefit. The dose reduction strategy resulted in a mean cost saving of €3,820 (95(th) percentile –€3,099 to –€4,509) per patient over a period of 12 months. There was an 83% chance that dose reduction would result in a reduction in quality adjusted life years (mean –0.02 (95(th) percentile –0.06 to 0.02). In conclusion, dose reduction of biologics resulted in substantial cost savings with an acceptable reduction in quality of life. |
format | Online Article Text |
id | pubmed-9309701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Society for Publication of Acta Dermato-Venereologica |
record_format | MEDLINE/PubMed |
spelling | pubmed-93097012022-10-20 Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study ATALAY, Selma VAN DEN REEK, Juul M. P. A. OTERO, Marisol E. NJOO, Marcellus D. MOMMERS, Johannes M. OSSENKOPPELE, Paul M. KOETSIER, Marjolein I. BERENDS, Maartje A. VAN DE KERKHOF, Peter C. M. GROENEWOUD, Hans M. M. DEN BROEDER, Alfons A. DE JONG, Elke M. G. J. KIEVIT, Wietske Acta Derm Venereol Investigative Report A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The aim of the current study was to perform a cost-utility analysis with a 12-month time horizon alongside this trial, using prospectively measured healthcare costs and quality-adjusted life years, based on Short-Form Six-Dimension utilities. Bootstrap analyses were used to calculate the decremental cost-utility ratio and the incremental net monetary benefit. The dose reduction strategy resulted in a mean cost saving of €3,820 (95(th) percentile –€3,099 to –€4,509) per patient over a period of 12 months. There was an 83% chance that dose reduction would result in a reduction in quality adjusted life years (mean –0.02 (95(th) percentile –0.06 to 0.02). In conclusion, dose reduction of biologics resulted in substantial cost savings with an acceptable reduction in quality of life. Society for Publication of Acta Dermato-Venereologica 2020-12-01 /pmc/articles/PMC9309701/ /pubmed/33196101 http://dx.doi.org/10.2340/00015555-3692 Text en © 2020 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license |
spellingShingle | Investigative Report ATALAY, Selma VAN DEN REEK, Juul M. P. A. OTERO, Marisol E. NJOO, Marcellus D. MOMMERS, Johannes M. OSSENKOPPELE, Paul M. KOETSIER, Marjolein I. BERENDS, Maartje A. VAN DE KERKHOF, Peter C. M. GROENEWOUD, Hans M. M. DEN BROEDER, Alfons A. DE JONG, Elke M. G. J. KIEVIT, Wietske Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study |
title | Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study |
title_full | Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study |
title_fullStr | Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study |
title_full_unstemmed | Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study |
title_short | Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study |
title_sort | health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the condor study |
topic | Investigative Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309701/ https://www.ncbi.nlm.nih.gov/pubmed/33196101 http://dx.doi.org/10.2340/00015555-3692 |
work_keys_str_mv | AT atalayselma healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT vandenreekjuulmpa healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT oteromarisole healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT njoomarcellusd healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT mommersjohannesm healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT ossenkoppelepaulm healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT koetsiermarjoleini healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT berendsmaartjea healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT vandekerkhofpetercm healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT groenewoudhansmm healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT denbroederalfonsa healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT dejongelkemgj healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy AT kievitwietske healtheconomicconsequencesofatightlycontrolleddosereductionstrategyforadalimumabetanerceptandustekinumabcomparedwithstandardpsoriasiscareacostutilityanalysisofthecondorstudy |